Outcome of COVID‐19 in multiple myeloma patients in relation to treatment

по Susek, Katharina Helene, Gran, Charlotte, Ljunggren, Hans‐Gustaf, Alici, Evren, Nahi, Hareth
Опубликовано в: Eur J Haematol (2020)

Comparative evaluation of involved free light chain and monoclonal spike as markers for progression from monoclonal gammopathy of undetermined significance to multiple myeloma

по Gran, Charlotte, Liwing, Johan, Wagner, Arnika Kathleen, Verhoek, Andre, Gezin, Ana, Alici, Evren, Nahi, Hareth
Опубликовано в: Am J Hematol (2020)

The Use of Novel Drugs Can Effectively Improve Response, Delay Relapse and Enhance Overall Survival in Multiple Myeloma Patients with Renal Impairment

по Uttervall, Katarina, Duru, Adil D., Lund, Johan, Liwing, Johan, Gahrton, Gösta, Holmberg, Erik, Aschan, Johan, Alici, Evren, Nahi, Hareth
Опубликовано 2014

Deletion of Chromosomal Region 8p21 Confers Resistance to Bortezomib and Is Associated with Upregulated Decoy TRAIL Receptor Expression in Patients with Multiple Myeloma

по Duru, Adil Doganay, Sutlu, Tolga, Wallblom, Ann, Uttervall, Katarina, Lund, Johan, Stellan, Birgitta, Gahrton, Gösta, Nahi, Hareth, Alici, Evren
Опубликовано в: PLoS One (2015)

Infectious complications and NK cell depletion following daratumumab treatment of Multiple Myeloma

по Nahi, Hareth, Chrobok, Michael, Gran, Charlotte, Lund, Johan, Gruber, Astrid, Gahrton, Gösta, Ljungman, Per, Wagner, Arnika Kathleen, Alici, Evren
Опубликовано в: PLoS One (2019)

Dynamic follow‐up of smoldering multiple myeloma identifies a subset of patients at high risk of progression

по Gran, Charlotte, Luong, Vincent, Bruchfeld, Johanna B., Liwing, Johan, Afram, Gabriel, Lund, Johan, Usmani, Saad, Alici, Evren, Nahi, Hareth
Опубликовано в: Am J Hematol (2020)

Functional Assessment for Clinical Use of Serum-Free Adapted NK-92 Cells

по Chrobok, Michael, Dahlberg, Carin I. M., Sayitoglu, Ece Canan, Beljanski, Vladimir, Nahi, Hareth, Gilljam, Mari, Stellan, Birgitta, Sutlu, Tolga, Duru, Adil Doganay, Alici, Evren
Опубликовано в: Cancers (Basel) (2019)

EZH2 inhibition in multiple myeloma downregulates myeloma associated oncogenes and upregulates microRNAs with potential tumor suppressor functions

по Alzrigat, Mohammad, Párraga, Alba Atienza, Agarwal, Prasoon, Zureigat, Hadil, Österborg, Anders, Nahi, Hareth, Ma, Anqi, Jin, Jian, Nilsson, Kenneth, Öberg, Fredrik, Kalushkova, Antonia, Jernberg-Wiklund, Helena
Опубликовано в: Oncotarget (2016)

Outcome and survival of myeloma patients diagnosed 2008–2015. Real-world data on 4904 patients from the Swedish Myeloma Registry

по Blimark, Cecilie Hveding, Turesson, Ingemar, Genell, Anna, Ahlberg, Lucia, Björkstrand, Bo, Carlson, Kristina, Forsberg, Karin, Juliusson, Gunnar, Linder, Olle, Mellqvist, Ulf-Henrik, Nahi, Hareth, Kristinsson, Sigurdur Y.
Опубликовано в: Haematologica (2018)

The polycomb group protein BMI-1 inhibitor PTC-209 is a potent anti-myeloma agent alone or in combination with epigenetic inhibitors targeting EZH2 and the BET bromodomains

по Alzrigat, Mohammad, Párraga, Alba Atienza, Majumder, Muntasir Mamun, Ma, Anqi, Jin, Jian, Österborg, Anders, Nahi, Hareth, Nilsson, Kenneth, Heckman, Caroline A., Öberg, Fredrik, Kalushkova, Antonia, Jernberg-Wiklund, Helena
Опубликовано в: Oncotarget (2017)

Health resource utilization associated with skeletal-related events: results from a retrospective European study

по Body, Jean-Jacques, Pereira, João, Sleeboom, Harm, Maniadakis, Nikos, Terpos, Evangelos, Acklin, Yves Pascal, Finek, Jindrich, Gunther, Oliver, Hechmati, Guy, Mossman, Tony, Costa, Luis, Rogowski, Wojciech, Nahi, Hareth, von Moos, Roger
Опубликовано в: Eur J Health Econ (2015)

Pharmacogenetic study of the impact of ABCB1 single-nucleotide polymorphisms on lenalidomide treatment outcomes in patients with multiple myeloma: results from a phase IV observati...

по Jakobsen Falk, Ingrid, Lund, Johan, Gréen, Henrik, Gruber, Astrid, Alici, Evren, Lauri, Birgitta, Blimark, Cecilie, Mellqvist, Ulf-Henrik, Swedin, Agneta, Forsberg, Karin, Carlsson, Conny, Hardling, Mats, Ahlberg, Lucia, Lotfi, Kourosh, Nahi, Hareth
Опубликовано в: Cancer Chemother Pharmacol (2017)

Active enhancer and chromatin accessibility landscapes chart the regulatory network of primary multiple myeloma

по Jin, Yi, Chen, Kenian, De Paepe, Ayla, Hellqvist, Eva, Krstic, Aleksandra D., Metang, Lauren, Gustafsson, Charlotte, Davis, Richard E., Levy, Yair M., Surapaneni, Rakesh, Wallblom, Ann, Nahi, Hareth, Mansson, Robert, Lin, Yin C.
Опубликовано в: Blood (2018)

Subcutaneous daratumumab in Asian patients with heavily pretreated multiple myeloma: subgroup analyses of the noninferiority, phase 3 COLUMBA study

по Iida, Shinsuke, Ishikawa, Takayuki, Min, Chang Ki, Kim, Kihyun, Yeh, Su Peng, Usmani, Saad Z., Mateos, Maria-Victoria, Nahi, Hareth, Heuck, Christoph, Qin, Xiang, Parasrampuria, Dolly A., Gries, Katharine S., Qi, Ming, Bahlis, Nizar, Ito, Shigeki
Опубликовано в: Ann Hematol (2021)

Chimeric antigen receptor T-cell therapy for multiple myeloma: a consensus statement from The European Myeloma Network

по Moreau, Philippe, Sonneveld, Pieter, Boccadoro, Mario, Cook, Gordon, Mateos, Ma Victoria, Nahi, Hareth, Goldschmidt, Hartmut, Dimopoulos, Meletios A., Lucio, Paulo, Bladé, Joan, Delforge, Michel, Hajek, Roman, Ludwig, Heinz, Facon, Thierry, Miguel, Jesus F. San, Einsele, Hermann
Опубликовано в: Haematologica (2019)

Exposure‐Response and Population Pharmacokinetic Analyses of a Novel Subcutaneous Formulation of Daratumumab Administered to Multiple Myeloma Patients

по Luo, Man (Melody), Usmani, Saad Z., Mateos, Maria‐Victoria, Nahi, Hareth, Chari, Ajai, San‐Miguel, Jesus, Touzeau, Cyrille, Suzuki, Kenshi, Kaiser, Martin, Carson, Robin, Heuck, Christoph, Qi, Ming, Zhou, Honghui, Sun, Yu‐Nien, Parasrampuria, Dolly A.
Опубликовано в: J Clin Pharmacol (2020)

Thalidomide and dexamethasone vs. bortezomib and dexamethasone for melphalan refractory myeloma: a randomized study

по Hjorth, Martin, Hjertner, Øyvind, Knudsen, Lene Meldgaard, Gulbrandsen, Nina, Holmberg, Erik, Pedersen, Per Trøllund, Andersen, Niels Frost, Andréasson, Björn, Billström, Rolf, Carlson, Kristina, Carlsson, Margaretha S, Flogegård, Max, Forsberg, Karin, Gimsing, Peter, Karlsson, Torbjörn, Linder, Olle, Nahi, Hareth, Othzén, Annika, Swedin, Agneta
Опубликовано 2012

The multiple myeloma risk allele at 5q15 lowers ELL2 expression and increases ribosomal gene expression

по Ali, Mina, Ajore, Ram, Wihlborg, Anna-Karin, Niroula, Abhishek, Swaminathan, Bhairavi, Johnsson, Ellinor, Stephens, Owen W, Morgan, Gareth, Meissner, Tobias, Turesson, Ingemar, Goldschmidt, Hartmut, Mellqvist, Ulf-Henrik, Gullberg, Urban, Hansson, Markus, Hemminki, Kari, Nahi, Hareth, Waage, Anders, Weinhold, Niels, Nilsson, Björn
Опубликовано в: Nat Commun (2018)

European Perspective on Multiple Myeloma Treatment Strategies in 2014

по Ludwig, Heinz, Sonneveld, Pieter, Davies, Faith, Bladé, Joan, Boccadoro, Mario, Cavo, Michele, Morgan, Gareth, de la Rubia, Javier, Delforge, Michel, Dimopoulos, Meletios, Einsele, Hermann, Facon, Thierry, Goldschmidt, Hartmut, Moreau, Philippe, Nahi, Hareth, Plesner, Torben, San-Miguel, Jesús, Hajek, Roman, Sondergeld, Pia, Palumbo, Antonio
Опубликовано 2014

Lenalidomide versus lenalidomide + dexamethasone prolonged treatment after second‐line lenalidomide + dexamethasone induction in multiple myeloma

по Lund, Johan, Gruber, Astrid, Lauri, Birgitta, Duru, Adil Doganay, Blimark, Cecilie, Swedin, Agneta, Hansson, Markus, Forsberg, Karin, Ahlberg, Lucia, Carlsson, Conny, Waage, Anders, Gimsing, Peter, Vangsted, Annette Juul, Frølund, Ulf, Holmberg, Erik, Gahrton, Gösta, Alici, Evren, Hardling, Mats, Mellqvist, Ulf‐Henrik, Nahi, Hareth
Опубликовано в: Cancer Med (2018)